세계의 장 질환 검사 시장 : 규모, 점유율 및 동향 분석(질환별, 지역별), 부문별 예측(2025-2030년)

Enteric Disease Testing Market Size, Share, & Trends Analysis Report By Disease (Bacterial, Viral, Parasitic), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2025 - 2030

US $ 4,950 ￦ 6,884,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 5,950 ￦ 8,275,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 7,950 ￦ 11,056,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 장 질환 검사 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 장 질환 검사 시장 규모는 2030년까지 47억 4,000만 달러에 달할 것으로 예측되며, 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 3.1%로 확대될 것으로 예측되고 있습니다. 장 질환의 이환율 증가와 고도의 진단 기술의 채용 증가가 시장 성장의 주요 요인입니다.

라이프 스타일과 소비자의 선호도 변화로 인해 여러 지역에서 소화기 감염의 발생률이 증가하여 장 질환 검사 솔루션에 대한 수요가 증가하고 있습니다. 여러 정부 기관이 공중 위생의 보호와 발생 방지에 주력하고 있는 것도 향후 수년간 이 업계의 성장을 가속할 것으로 예측됩니다.

검진 프로그램, 계발 캠페인, 특정 복지 제도 등 의료 개선을 위한 정부의 대처는 시장의 성장을 가속할 것으로 예측되고 있습니다. 또, BEAM(세균, 장내 세균, 아메바, 진균) 대시보드의 관리에도 도움이 되어, 장 질환 발생 데이터를 일반의 열람자에게 제공합니다.

장 질환 검사 시장 : 분석 개요

• 세균성 부문은 일반적인 장 질환의 원인이 되는 대장균, 대장염균, 이질균, 살모넬라균 등의 많은 세균에 의해 2024년 장 질환 검사 시장의 약 60%의 점유율을 차지했습니다.
• 기생충 분야는 오염된 물과 식품, 다양한 지역에서 열악한 위생 시스템, 적절한 위생 상태의 부족으로 인한 장 질환의 증례가 증가하고 있기 때문에 성장이 예상됩니다.
• 대규모 감염확대를 막기 위한 고도의 진단기술을 특징으로 하는 개선된 의료 서비스를 제공하는데 여러 정부가 중점을 두게 되어 있는 것이 성장 기회를 만들어낼 것으로 예측됩니다.
• 북미는 견고한 의료 인프라, 주요 진단 기술 개발 기업과 생명 공학 기업의 존재 등의 요인으로부터 2024년에는 세계 업계를 지배했습니다.
• 지역 기관에 의한 예방 대책과 정부 출자의 연구 프로그램이 성장을 가속할 것으로 예측됩니다.
• 2025년 2월, BIOMERIEUX사는 이 회사의 새로운 검사 솔루션인 BIOFIRE FILMARRAY Gastrointestinal(GI) Panel Mid.가 미국 FDA로부터 인가를 받았다고 발표했습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 장 질환 검사 시장 : 변동 요인, 경향, 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 장 질환 검사 시장 : 분석 도구
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 장 질환 검사 시장 : 질환별 추정 및 동향 분석

• 질병별 대시보드
• 장 질환 검사 시장 : 업계 동향의 분석
• 세계의 장 질환 검사 시장 : 시장 규모와 동향 분석 : 질환별(2018-2030년)
• 세균성
  • 시장추계 및 예측(2018-2030년)
  • C. 디피실
  • 캄필로박터증
  • 콜레라
  • 대장균
  • H. 파일로리균
  • 살모넬라증
  • 세균성 이질
• 바이러스
  • 시장추계 및 예측(2018-2030년)
  • 로터바이러스
  • 노로바이러스
• 기생충
  • 시장추계 및 예측(2018-2030년)
  • 아메바증
  • 크립토스포리듐증
  • 디알디아증

제5장 장 질환 검사 시장 : 지역별 추정 및 동향 분석

• 시장 대시보드 : 지역별
• 시장 점유율 분석 : 지역별(2024년 및 2030년)
• 장 질환 검사 시장 : 주요 포인트, 지역별
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제6장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 히트맵 분석(2024년)
• 기업 프로파일
  • Abbott
  • BD
  • Biomerica
  • BIOMERIEUX
  • Bio-Rad Laboratories, Inc.
  • Cepheid
  • Coris Bioconcept
  • DiaSorin SpA
  • Meridian Bioscience
  • Quest Diagnostics Incorporated

JHS

영문 목차

영문목차

Enteric Disease Testing Market Growth & Trends:

The global enteric disease testing market size is anticipated to reach USD 4.74 billion by 2030 and is anticipated to expand at a CAGR of 3.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing incidence of enteric diseases and the rising adoption of advanced diagnostic technologies are the major factors contributing to market growth. According to the U.S. Center for Disease Control and Prevention, nearly 11 and 21 million cases of typhoid fever and approximately 5 million paratyphoid fever cases are recorded worldwide each year.

The increasing incidence of gastrointestinal infections in multiple regions, driven by changing lifestyles and consumer preferences, has generated greater demand for enteric disease testing solutions. Growing awareness regarding the severe effects of enteric diseases, if not intervened in time, has led to the rising number of tests. The focus of multiple government agencies on protecting public health and preventing outbreaks is also expected to drive the growth of this industry in the coming years.

Government initiatives for improved healthcare, including screening programs, awareness campaigns, and specific welfare schemes, are projected to fuel market growth. For instance, in the U.S., the Centers for Disease Control and Prevention (CDC) uses the System for Enteric Disease Response, Investigation, and Coordination (SEDRIC) to ensure efficient surveillance and response to disease outbreaks linked to food or animal contact. It also helps manage the BEAM (Bacteria, Enterics, Ameba, and Mycotics) Dashboard, which provides enteric disease outbreak data to public viewers. Such initiatives are expected to result in increased testing in the forecast period.

Enteric Disease Testing Market Report Highlights:

• The bacterial segment dominated the enteric disease testing market with nearly 60% share in 2024 owing to many bacteria, such as C. difficile, E. coli, Shigella, and Salmonella, which cause common enteric diseases.
• The parasitic segment is expected to experience growth due to increasing cases of enteric diseases driven by contaminated water and food, poor sanitation systems in various regions, and lack of adequate hygiene.
• The growing focus of multiple governments on offering improved healthcare services that feature advanced diagnostic technologies to prevent large-scale outbreaks is expected to create growth opportunities.
• North America dominated the global industry in 2024 owing to factors such as a robust healthcare infrastructure and the presence of key diagnostic technology developers and biotechnology companies.
• Preventive measures embraced by local agencies and government-funded research programs are anticipated to fuel growth.
• In February 2025, BIOMERIEUX announced that it received clearance from the U.S. FDA for its new testing solution, BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Outlook
  • 1.2.2. Regional Scope
  • 1.2.3. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease Outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Enteric Diseases Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Enteric Diseases Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis

Chapter 4. Enteric Diseases Testing: Disease Estimates & Trend Analysis

• 4.1. Disease Segment Dashboard
• 4.2. Enteric Diseases Testing Market: Industry Movement Analysis
• 4.3. Global Enteric Diseases Testing Market Size & Trend Analysis, by Disease , 2018 to 2030 (USD Million)
• 4.4. Bacterial
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. C. Difficile
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Campylobacteriosis
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Cholera
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. E. Coli
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. H. Pylori
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Salmonellosis
    • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.8. Shigellosis
    • 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Viral
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Rotavirus
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Norovirus
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Parasitic
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Amebiasis
    • 4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Cryptosporidiosis
    • 4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.4. Giardiasis
    • 4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Enteric Diseases Testing Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Dashboard
• 5.2. Regional Market Share Analysis, 2024 & 2030
• 5.3. Continuous bioprocessing market by Region: Key Takeaways
• 5.4. North America
  • 5.4.1. U.S.
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Canada
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Mexico
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. UK
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Germany
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. France
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Italy
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Spain
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Norway
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.7. Sweden
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework/ reimbursement structure
    • 5.5.7.3. Competitive scenario
    • 5.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.8. Denmark
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Regulatory framework/ reimbursement structure
    • 5.5.8.3. Competitive scenario
    • 5.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Japan
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. China
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. India
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Australia
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Regulatory framework/ reimbursement structure
    • 5.6.4.3. Competitive scenario
    • 5.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. South Korea
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Regulatory framework/ reimbursement structure
    • 5.6.5.3. Competitive scenario
    • 5.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Thailand
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Regulatory framework/ reimbursement structure
    • 5.6.6.3. Competitive scenario
    • 5.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Brazil
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Argentina
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. South Africa
    • 5.8.1.1. Key country dynamics
    • 5.8.1.2. Regulatory framework/ reimbursement structure
    • 5.8.1.3. Competitive scenario
    • 5.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Saudi Arabia
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Regulatory framework/ reimbursement structure
    • 5.8.2.3. Competitive scenario
    • 5.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.3. UAE
    • 5.8.3.1. Key country dynamics
    • 5.8.3.2. Regulatory framework/ reimbursement structure
    • 5.8.3.3. Competitive scenario
    • 5.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.4. Kuwait
    • 5.8.4.1. Key country dynamics
    • 5.8.4.2. Regulatory framework/ reimbursement structure
    • 5.8.4.3. Competitive scenario
    • 5.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key company heat map analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Abbott
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. BD
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Biomerica
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. BIOMERIEUX
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Bio-Rad Laboratories, Inc.
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. Cepheid
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Coris Bioconcept
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. DiaSorin S.p.A.
    • 6.4.8.1. Company overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Product benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Meridian Bioscience
    • 6.4.9.1. Company overview
    • 6.4.9.2. Financial performance
    • 6.4.9.3. Product benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Quest Diagnostics Incorporated
    • 6.4.10.1. Company overview
    • 6.4.10.2. Financial performance
    • 6.4.10.3. Product benchmarking
    • 6.4.10.4. Strategic initiatives

관련자료